SEARCH

SEARCH BY CITATION

References

  • 1
    Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural History of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998; 92: 72735.
  • 2
    Holowaty P, Miller AB, Rohan T, To T. Natural History of Dysplasia of the Uterine Cervix. J Natl Cancer Inst. 1999; 91: 2528.
  • 3
    Wright TC, Cox JT, Massad LS, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cyto-logical abnormalities. JAMA. 2002; 287: 21209.
  • 4
    Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004; 96: 28093.
  • 5
    Arbyn M, Dillner J, Van Ranst M, Buntinx F, Martin-Hirsch P, Paraskevaidis E. Re: Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst. 2004; 96: 14012.
  • 6
    Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH, National Cancer Institute. Interim guidelines for management of abnormal cervical cytology. JAMA. 1994; 271: 18669.
  • 7
    Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J, Segnan N. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme. Eur J Cancer. 1993; 29A: S1S38.
  • 8
    ASCUS-LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003; 188: 138392.
  • 9
    Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006; 24(S3): 7889.
  • 10
    Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197: 34655.
  • 11
    Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Anttila A, Nieminen P, Prendiville W. In: ArbynM, AnttilaA, JordanJ, RoncoG, SchenckU, SegnanN, WienerH, DanielJ, Von KarsaL, editors. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg : Office for Official Publications of the European Communities; 2008. p. 191232.
  • 12
    European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg : Office for Official Publications of the European Communities; 2008.
  • 13
    Moss S, Gray A, Legood R, Vessey M, Patnick J, Kitchener HC. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ. 2006; 332: 835.
  • 14
    Llewellyn H. Re: An alternative cost-effectiveness analysis of ThinPrep in the Australian setting. Aust N Z J Obstet Gynaecol. 2006; 46: 67.
  • 15
    Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol. 2005; 99: 711.
  • 16
    Solomon D, Schiffman MA, Tarone B. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 2939.
  • 17
    Sherman ME, Schiffman MA, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomised atypical squamous cells of undetermined significance/low-grade intraepithelial lesion triage study (ALTS). J Natl Cancer Inst. 2002; 94: 1027.
  • 18
    Luff RD, National Cancer Institute. The revised Bethesda system for reporting cervical/vaginal cytological diagnoses. Report of the 1991 Bethesda Workshop. Acta Cytol. 1992; 36: 2736.
  • 19
    Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman ME, Wilbur D, Wright TC, Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 21149.
  • 20
    Evans DMD, Hudson EA, Brown CL, Boddington MM, Hughes HE, Mackenzie EFD, Marshall T. Terminology in gynaecological cytopathology: report of the working party of the BSCC. J Clin Pathol. 1986; 39: 93344.
  • 21
    Dudding N, Sutton J. BSCC terminology conference, koilocytosis and mild dyskaryosis. Cytopathology. 2002; 13: 37981.
  • 22
    Dersimonian R, Laird NM. Meta-analysis in clinical trials. Controlled Clin Trials. 1986; 7: 17788.
  • 23
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954; 10: 10129.
  • 24
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 55760.
  • 25
    Light RJ, Singer JD, Willet JB. In: CooperH, editors. The handbook of research synthesis. New York : Russel Sage Foundation; 1994. p. 43954.
  • 26
    Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. J. Wiley and Sons, Chichester , UK : 2000.
  • 27
    Harris R, Bradburm M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed- and random-effects meta-analysis. The Stata Journal. 2008; 8: 326.
  • 28
    Bradburn M, Deeks JJ, Altman DG. Metan – an alternative meta-analysis command. Stata Technical Bulletin. 1999; 8: 86100.
  • 29
    Sasieni P, Stepniewska K, Altman D. Test for trend across ordered groups revisited. Stata Technical Bulletin. 1996; 6: 1936.
  • 30
    Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998; 351: 1237.
  • 31
    Sharp S. Meta-analysis regression. Stata Technical Bulletin. 1998; 7: 14855.
  • 32
    Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999; 18: 2693708.
  • 33
    Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280: 16901.
  • 34
    McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003; 157: 9403.
  • 35
    Sharp S, Sterne J. Meta-analysis. Stata Technical Bulletin. 1997; 914.
  • 36
    Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman ME, Hartinger JS, Mclntosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal papanicolaou results. JAMA. 1999; 281: 160510.
  • 37
    Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol. 2000; 95: 8217.
  • 38
    Lytwyn A, Sellors JW, Mahony JB. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. CMAJ. 2000; 163: 7017.
  • 39
    Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM Jr. Prediction of cerviacal intraepithelial neoplasia grade 2–3 using risk assessement and human papillo-mavirus testing in women with atypia on papanicolaou smears. Obstet Gynecol. 2000; 96: 4106.
  • 40
    Morin C, Bariati C, Bouchard C, Fortier M, Roy M, Moore L, Meisels A. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. J Reprod Med. 2001; 46: 799805.
  • 41
    Rebello G, Hallam N, Smart G, Farquharson D, McCafferty J. Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study. BMJ. 2001; 322: 8945.
  • 42
    Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, De Schipper FA, Meijer CJLM. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol. 2001; 195: 3006.
  • 43
    Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening cervical abnormalities. Comparison of sesitivity, specificity, and frequency of referral. JAMA. 2002; 288: 174957.
  • 44
    Pretorius RG, Peterson P, Novak S, Azizi F, Sadeghi M, Lorincz AT. Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy. J Reprod Med. 2002; 47: 2906.
  • 45
    Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener HC, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003; 362: 18716.
  • 46
    Guyot A, Karim S, Kyi MS, Fox J. Evaluation of adjunctive HPV testing by hybrid capture II(R) in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy. BMC Infectious Diseases. 2003; 3: 17.
  • 47
    Lonky NM, Felix JC, Naidu YM, Wolde Tsadik G. Triage of atypical squamous cells of undetermined significance with Hybrid Capture II: colposcopy and histo-logic human papillomavirus correlation. Obstet Gynecol. 2003; 101: 4819.
  • 48
    Wensveen C, Kagie M, Veldhuizen R, De Groot C, Denny L, Zwinderman K, Trimbos B. Detection of cervical intraep-ithelial neoplasia in women with atypical squamous or glandular cells of undetermined significance cytology: a prospective study. Acta Obstet Gynecol Scand. 2003; 82: 8839.
  • 49
    Bruner KS, Davey DD. ASC-US and HPV testing in women aged 40 years and over. Diagn Cytopathol. 2004; 31: 35861.
  • 50
    Rowe LR, Aldeen W, Bentz JS. Prevalence and typing of HPV DNA by Hybrid Capture II in women with ASCUS, ASC-H, LSIL, and AGC on ThinPrep Pap tests. Diagn Cytopathol. 2004; 30: 42632.
  • 51
    Andersson S, Dillner L, Elfgren K, Mints M, Persson M, Rylander E. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytolog-ical abnormalities. Acta Obstet Gynecol Scand. 2005; 84: 9961000.
  • 52
    Dalla Palma P, Pojer A, Girlando S. HPV triage of women with atypical squamous cells of undetermined significance: a 3-year experience in an Italian organized programme. Cytopathology. 2005; 16: 226.
  • 53
    Giovannelli L, Capra G, Lama A, Bustinto T, Genco A, Valenti FM, Pinto G, Matranga D, Ammatuna P. Atypical squamous cells of undetermined significance-favour reactive compared to atypical squamous cells of undetermined significance-favour dysplasia: association with cervical intraepithelial lesions and human papillomavirus infection. J Clin Virol. 2005; 33: 2816.
  • 54
    Kendall BS, Bush AC, Olsen CH, Zahn CM. Reflex high-risk human papillomavirus testing for women with atypical squamous cells of undetermined significance in cytologic smears: effects since implementation in a large clinical practice. Am J Clin Pathol. 2005; 123: 5248.
  • 55
    Nieh S, Chen SF, Chu TY, Lai HC, Lin YS, Fu E, Gau CH. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol. 2005; 97: 3540.
  • 56
    Bergeron C, Cas F, Fagnani F, Contrepas A, Wadler R, Poveda JD. Assessment of human papillomavirus testing on liquid-based CYTO-screen system for women with atypical squamous cells of undetermined significance. Effect of age. Gynecol Obstet Fertil. 2006; 34: 3126.
  • 57
    Kelly D, Kincaid E, Fansler Z, Rosenthal DL, Clark DP. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProExtrade mark C). Cancer. 2006; 108: 494500.
  • 58
    Kiatpongsan S, Niruthisard S, Mutirangura A, Trivijitsilp P, Vasuratna A, Chaithongwongwatthana S, Lertkhachonsuk R. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. Int J Gynecol Cancer. 2006; 16: 2625.
  • 59
    Ko V, Tambouret RH, Kuebler DL, Black-Schaffer WS, Wilbur DC. Human papillomavirus testing using hybrid capture II with surepath collection: initial evaluation and longitudinal data provide clinical validation for this method. Cancer. 2006; 108: 46874.
  • 60
    Monsonego J, Pintos J, Semaille C, Beumont M, Dachez R, Zerat L, Bianchi A, Franco E. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 2006; 16: 5918.
  • 61
    Selvaggi SM. ASC-US and high-risk HPV testing: performance in daily clinical practice. Diagn Cytopathol. 2006; 34: 7313.
  • 62
    Wright JD, Rader JS, Davila R, Powell MA, Mutch DG, Gao F, Gibb RK. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. Obstet Gynecol. 2006; 107: 8229.
  • 63
    Cuschieri KS, Graham C, Moore C, Cubie HA. Human Papillomavirus testing for the management of low-grade cervical abnormalities in the UK-Influence of age and testing strategy. J Clin Virol. 2007; 38: 148.
  • 64
    Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Palma PD, Mistro AD, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer. 2007; 43: 47680.
  • 65
    You K, Liang X, Qin F, Guo Y, Geng L. High-risk human papillomavirus DNA testing and high-grade cervical intraepithelial lesions. Aust N Z J Obstet Gynaecol. 2007; 47: 1414.
  • 66
    Lee NW, Kim D, Park JT, Kim A. Is the human papillomavirus test in combination with the Papanicolaou test useful for management of patients with diagnoses of atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions? Arch Pathol Lab Med. 2001; 125: 14537.
  • 67
    Boardman LA, Stanko C, Weitzen S, Sung J. Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol. 2005; 105: 7416.
  • 68
    Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Woodward L. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract. 1998; 46: 13641.
  • 69
    Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS. High-risk HPV DNA detection by Hybrid Capture II. An adjunc-tive test for mildly abnormal cytologic smears in women > or = 50 years of age. J Reprod Med. 2000; 45: 34550.
  • 70
    ALTS group, Anonymous. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000; 92: 397402.
  • 71
    ASCUS-LSIL Triage Study Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003; 188: 1393400.
  • 72
    Guido R, Schiffman MA, Solomon D, Burke L. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol. 2003; 188: 14015.
  • 73
    Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neo-plasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007; 197: 3405.
  • 74
    Legood R, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs, and cost effectiveness of testing for human papillo-mavirus to manage low grade cytological abnormalities: modelling study. BMJ. 2006; 332: 7985.
  • 75
    Bais AG, Rebolj M, Snijders PJ, De Schipper FA, Van Der Meulen DA, Verheijen RH, Voorhorst F, Van Ballegooijen M, Meijer CJ, Helmerhorst TJ. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer. 2005; 116: 1229.
  • 76
    Berkhof J, De Bruijne MC, Zielinski GD, Bulkmans NW, Rozendaal L, Snijders PJ, Verheijen RH, Meijer CJ. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer. 2006; 118: 175968.
  • 77
    Sawaya GF. A 21-year-old woman with atypical squamous cells of undetermined significance. JAMA. 2005; 294: 22108.
  • 78
    Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005; 97: 14750.
  • 79
    Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 115764.
  • 80
    Franceschi S, Clifford GM. Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005; 97: 9389.
  • 81
    Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papil-lomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol. 2005; 124: 72232.
  • 82
    Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005; 97: 106671.
  • 83
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intra-epithelial or early invasive cervical lesions: a systematic review and meta-analysis of the literature. Lancet 2006; 367: 48998.
  • 84
    Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. Peri-natal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: a meta-analysis. BMJ. 2008; 337: a1284.
  • 85
    Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB, Skomedal H, Thoresen SO, Hagmar B. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL pap smear. Int J Cancer. 2005; 114: 9736.
  • 86
    Arias-Pulido H, Narayan G, Vargas H, Mansukhani M, Murty VV. Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precan-cerous lesions. Mol Cancer. 2002; 1: 3.
  • 87
    Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol. 2002; 46: 259.
  • 88
    Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev. 2002; 11: 4838.
  • 89
    Von Knebel DM. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002; 38: 222942.
  • 90
    Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 34250.
  • 91
    Solomon D. Chapter 14: Role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr. 2003; 97101.
  • 92
    Tsoumpou I, Arbyn M, Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Paraskevaidis E. p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009; in press.
  • 93
    Wentzensen N, Bergeron C, Cas F, Vinokurova S, Von Knebel DM. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer. 2007; 111: 5866.
  • 94
    Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, Zorzi M, Cuzick J, Rizzolo R, Ronco G; New Technologies for Cervical Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008; 9: 93745.
  • 95
    Ko V, Nanji S, Tambouret RH, Wilbur DC. Testing for HPV as an objective measure for quality assurance in gynecologic cytology: positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio. Cancer. 2007; 111: 6773.
  • 96
    Arbyn M, Schenck U, Ellison E, Hanselaar A. Metaanalysis of the accuracy of rapid prescreening relative to full screening of pap smears. Cancer. 2003; 99: 916.
  • 97
    Depuydt CE, Arbyn M, Benoy IH, Vandepitte J, Vereecken A, Bogers JJ. Quality control for normal liquid based cytology: rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection? J Cell Mol Med. 2008; doi: 10.1111/j.1582-4934.2008.00379.x
  • 98
    Arbyn M, Cuzick J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention. Cancer Lett. 2008; in press.